Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 13, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$22.1B
sum of reported positions
Reported positions
660
Changes vs prior quarter
624
41 new · 54 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 354 measured positions in 8 quarters, the typical new or larger position finished +0.0 pts against the S&P 500 and 50% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $19.2B | $22.1B |
| Positions | 673 | 660 |
| Biggest line | — | NVIDIA 6% |
| 2.62M |
| $936M |
| 4.2% |
| 1.69M | $639M | 2.9% |
| 2.6M | $618M | 2.8% |
| 423K | $488M | 2.2% |
| 402K | $482M | 2.2% |
| 658K | $382M | 1.7% |
| 963K | $328M | 1.5% |
| 713K | $309M | 1.4% |
| 843K | $297M | 1.3% |
| 1.16M | $293M | 1.3% |
| 606K | $289M | 1.3% |
| 761K | $229M | 1.0% |
| 644K | $221M | 1.0% |
| 379K | $194M | 0.9% |
| 1.42M | $182M | 0.8% |
| 1.35M | $179M | 0.8% |
| 544K | $178M | 0.8% |
| 2.01M | $176M | 0.8% |
| 347K | $174M | 0.8% |
| 429K | $171M | 0.8% |
| 210K | $159M | 0.7% |
| 271K | $152M | 0.7% |
Corning Inc. (GLW)
67K → 62K shares (−8%)
Stoke Therapeutics (STOK)
502K → 480K shares (−4%)
Valero Energy (VLO)
101K → 60K shares (−40%)
Boston Scientific (BSX)
1.26M → 367K shares (−71%)
Moonlake Immunotherapeutics (MLTX)
818K → 770K shares (−6%)
Cloudflare (NET)
61K → 58K shares (−4%)
Medpace (MEDP)
103K → 26K shares (−75%)
Vaxcyte (PCVX)
315K → 208K shares (−34%)
Advanced Drainage Systems (WMS)
81K → 77K shares (−6%)
Illinois Tool Works (ITW)
48K → 44K shares (−9%)
Scholar Rock Holding (SRRK)
226K → 216K shares (−4%)
Ypf Sociedad Anonima (YPF)
444K → 250K shares (−44%)
Howmet Aerospace (HWM)
42K → 42K shares (−2%)
Colgate-Palmolive (CL)
128K → 121K shares (−5%)
Dover Corporation (DOV)
52K → 49K shares (−5%)
APOGEE THERAPEUTICS INC
224K → 80K shares (−64%)
MetLife (MET)
130K → 125K shares (−4%)
Sionna Therapeutics (SION)
237K → 233K shares (−2%)
Olema Pharmaceuticals (OLMA)
760K → 751K shares (−1%)
Nurix Therapeutics (NRIX)
534K → 378K shares (−29%)
Ocular Therapeutix (OCUL)
949K → 908K shares (−4%)
Watts Water Technologies (WTS)
35K → 23K shares (−35%)
Service Corp Intl (SCI)
360K → 114K shares (−68%)
American Tower (AMT)
54K → 52K shares (−5%)
Maze Therapeutics (MAZE)
278K → 274K shares (−2%)
